August 21, 2024
Gosselies, Belgium
Bioxodes reports positive DMC meeting for BIOX-101 Phase 2a trial in intracerebral hemorrhagic stroke
Read the full press release
Press Releases
- Newsroom
- /Press Releases
-
-
June 27, 2024
Gosselies, Belgium
Bioxodes meets first Phase 2a patient enrollment milestone with BIOX-101 in intracerebral hemorrhagic stroke
Read the full press release -
May 16, 2024
Gosselies, Belgium
Bioxodes receives European Patent Office intention to grant patent, offering lead asset broad protection in thromboinflammation
Read the full press release -
February 20, 2024
Gosselies, Belgium
Bioxodes to present first-in-class drug candidate BIOX-101 for hemorrhagic stroke to investors and pharmaceutical community in range of conferences
Read the full press release -
November 21, 2023
Gosselies, Belgium
Bioxodes closes €12 million in Series A funding round
Funding will enable Bioxodes to continue clinical development of drug candidate for patients with intracerebral hemorrhage. Recruitment of first patient for phase IIa proof-of-concept clinical trial due before end of Q4, 2023
Read the full press release -
August 23, 2023
London, United Kingdom
Head of Belgian Biotech Firm Wins Business Worldwide Magazine CEO Award
LONDON, Aug. 23, 2023 /PRNewswire/ -- In the 2023 Business Worldwide Magazine CEO Awards, Marc Dechamps, the CEO of Belgian biotech firm Bioxodes, receives an acknowledgment as he is named 'Biotechnology CEO of the Year - Europe'. Marc Dechamps was the outright winner in his category, for his ground-breaking work in the field of thrombo-inflammation or stroke.
Read the full press release -
April 26, 2023
Gosselies, Belgium
Bioxodes presents latest developments at key international conferences
• Bioxodes to give presentation at Bio€quity (May 14-16) and present posters at ESOC (May 24-26) and ISTH (June 24-28) • Company prepares Series A extension funding round for upcoming phase IIa and preparation of phase IIb clinical trials
Read the full press release -
December 15, 2022
Gosselies, Belgium
Bioxodes to present at Biotech Showcase™ 2023
Bioxodes to present at Biotech Showcase™ 2023 about its breakthrough drug candidate Ir-CPI for the prevention of thrombosis and neuroinflammation in hemorrhagic stroke patients.
Read the full press release -
October 18, 2022
Marche-en-Famenne, Belgium
Bioxodes appoints Marc Dechamps as new CEO
Read the full press release -
November 02, 2021
Marche-en-Famenne, Belgium
Bioxodes appoints Dr. Hans Warrinnier as Chief Medical Officer
Read the full press release -
April 29, 2021
Marche-en-Famenne, Belgium
Bioxodes announces the completion of the active phase of its First-in-Human study performed in healthy adult volunteers with Ir-CPI
Read the full press release -
October 15, 2019
Marche-en-Famenne, Belgium
Bioxodes obtains authorization to launch Phase I trial of its antithrombotic drug, Ir-CPI, in healthy male volunteers
Read the full press release -
June 01, 2019
Marche-en-Famenne, Belgium
Bioxodes raises EUR 7.65 million to cover its clinical Phase I study and to obtain first proofs of efficacy in patients
Read the full press release -
June 01, 2015
Marche-en-Famenne, Belgium
Bioxodes raises EUR 7.9 million to bring Ir-CPI to the clinic
Read the full press release -
January 01, 2015
Marche-en-Famenne, Belgium
Bioxodes’ antithrombotic meets development milestones – Company to launch Series A financing round to bring product to the clinic
Read the full press release -
November 01, 2013
Marche-en-Famenne, Belgium
Bioxodes raises EUR 2.6 million to develop antithrombotic peptide derived from tick saliva
Read the full press release